The role of prison-based interventions for hepatitis C virus (HCV) micro-elimination among people who inject drugs in Montreal, Canada

被引:20
|
作者
Godin, Arnaud [1 ]
Kronfli, Nadine [2 ,3 ]
Cox, Joseph [1 ,2 ,3 ]
Alary, Michel [4 ,5 ,6 ]
Maheu-Giroux, Mathieu [1 ]
机构
[1] McGill Univ, Sch Populat & Global Hlth, Dept Epidemiol Biostat & Occupat Hlth, Fac Med, 1020 Ave Pins Ouest,Rm 43, Montreal, PQ H3A 1A2, Canada
[2] McGill Univ, Div Infect Dis, Dept Med, Hlth Ctr, Montreal, PQ, Canada
[3] McGill Univ, Chron Viral Illness Serv, Hlth Ctr, Montreal, PQ, Canada
[4] Univ Laval, Dept Med Sociale & Prevent, Quebec City, PQ, Canada
[5] Univ Laval, Axe Sante Populat & Prat Optimales Sante, Ctr Rech CHU Quebec, Quebec City, PQ, Canada
[6] Inst Natl Sante Publ Quebec, Quebec City, PQ, Canada
基金
加拿大健康研究院;
关键词
People in prison; People who inject drugs; Linkage to care; HCV; Micro-elimination; SPONTANEOUS CLEARANCE; RELEASE; CARE; IMPACT; METAANALYSIS; INFECTION; COMMUNITY; HIV; INCARCERATION; FACILITATORS;
D O I
10.1016/j.drugpo.2020.102738
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: In Canada, hepatitis C virus (HCV) transmission primarily occurs among people who inject drugs (PWID) and people with experience in the prison system bare a disproportionate disease burden. These overlap-ping groups of individuals have been identified as priority populations for HCV micro-elimination in Canada, which is currently not on track to achieve its elimination targets. Considering the missed opportunities to inter-vene in provincial prisons, this study aims to estimate the population-level impact of prison-based interventions and post-release risk reduction strategies on HCV transmission among PWID in Montreal, a Canadian city with high HCV burden. Methods: A dynamic HCV transmission model among PWID was developed and calibrated to community and prison bio-behavioural surveys in Montreal. Then, the relative impact of prison-based testing and treatment or post-release linkage to care (both 90% testing and 75% treatment coverage), alone or in combination with strategies that reduce the heightened post-release transmission risk by 50%, was estimated from 2018 to 2030, and compared to counterfactual scenarios. Results: Prison-based test-and-treat strategies could lead to the greatest declines in incidence (48%; 95%CrI: 38-57%) over 2018-2030 and prevent the most new first chronic infections (22%; 95%CrI: 16 - 28%) among people never exposed to HCV. Prison testing and post-release linkage to care lead to a slightly lower decrease in incidence and prevented fraction of new chronic infections. Combining test-and-treat with risk reduction measures could further its epidemiological impact, preventing 35% (95%CrI: 29 - 40%) of new first chronic infections. When implemented concomitantly with community-based treatment scale-up, prison-based interventions had synergistic effects, averting a higher fraction of new first chronic infections. Conclusion: Offering HCV testing and treatment in provincial prisons, where incarcerations are frequent and sentences short, could change the course of the HCV epidemic in Montreal. Prison-based interventions with potential integration of post-release risk reduction measures should be considered as an integral part of HCV micro-elimination strategies in this setting.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland
    Stone, Jack
    Martin, Natasha K.
    Hickman, Matthew
    Hutchinson, Sharon J.
    Aspinall, Esther
    Taylor, Avril
    Munro, Alison
    Dunleavy, Karen
    Peters, Erica
    Bramley, Peter
    Hayes, Peter C.
    Goldberg, David J.
    Vickerman, Peter
    ADDICTION, 2017, 112 (07) : 1302 - 1314
  • [2] Hepatitis C virus micro-elimination in people who inject drugs: Challenges and chance in Taiwan and worldwide
    Tai, Chi-Ming
    Yu, Ming-Lung
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2024, 40 (02): : 112 - 118
  • [3] Prison-based interventions are key to achieving HCV elimination among people who inject drugs in New South Wales, Australia: A modelling study
    Stone, Jack
    Lim, Aaron G.
    Dore, Gregory J.
    Borquez, Annick
    Geddes, Louise
    Gray, Richard
    Grebely, Jason
    Hajarizadeh, Bezhad
    Iversen, Jenny
    Maher, Lisa
    Valerio, Heather
    Martin, Natasha K.
    Hickman, Matthew
    Lloyd, Andrew R.
    Vickerman, Peter
    LIVER INTERNATIONAL, 2023, 43 (03) : 569 - 579
  • [4] Macro-efforts for the micro-elimination of hepatitis C targeting people who inject drugs
    Lee, Shui-Shan
    Crofts, Nick
    Hung, Chien-Ching
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2019, 85 : 141 - 142
  • [6] Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago
    Tatara, Eric
    Gutfraind, Alexander
    Collier, Nicholson T.
    Echevarria, Desarae
    Cotler, Scott J.
    Major, Marian E.
    Ozik, Jonathan
    Dahari, Harel
    Boodram, Basmattee
    PLOS ONE, 2022, 17 (03):
  • [7] Sexual behaviour as a risk factor for hepatitis C virus infection among people who inject drugs in Montreal, Canada
    Jacka, Brendan
    Roy, Elise
    Hoj, Stine
    Minoyan, Nanor
    Artenie, Andreea Adelina
    Zang, Geng
    Jutras-Aswad, Didier
    Bruneau, Julie
    JOURNAL OF VIRAL HEPATITIS, 2019, 26 (12) : 1413 - 1422
  • [8] Is hepatitis C virus (HCV) elimination achievable among people who inject drugs in Tijuana, Mexico? A modeling analysis
    Marquez, Lara K.
    Cepeda, Javier A.
    Borquez, Annick
    Strathdee, Steffanie A.
    Gonzalez-Zuniga, Patricia E.
    Fleiz, Clara
    Rafful, Claudia
    Garfein, Richard S.
    Kiene, Susan M.
    Brodine, Stephanie
    Martin, Natasha K.
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2021, 88
  • [9] Hepatitis C Virus (HCV) Prevalence among People who Inject Drugs (PWIDs) in Portugal
    Razavi, Homie
    Calinas, Filipe
    Duran, Domingos
    Estes, Chris R.
    Felix, Jorge
    Maltez, Fernando
    Marinho, Rui T.
    Mendao, Luis
    Vilar, Graca
    HEPATOLOGY, 2015, 62 : 1116A - 1116A
  • [10] Hepatitis C Virus (HCV) Prevalence among People who Inject Drugs (PWIDs) in Switzerland
    Negro, Francesco
    Bruggmann, Philip
    Blach, Sarah
    Deltenre, Pierre
    Fehr, Jan
    Kouyos, Roger
    Lavanchy, Daniel
    Mullhaupt, Beat
    Razavi, Homie
    Schmid, Patrick
    Semela, David
    Stoeckle, Martin
    Rauch, Andri
    HEPATOLOGY, 2015, 62 : 1095A - 1095A